pharma report anti infect ives

Upload: joash-eleazar-casucog

Post on 09-Apr-2018

218 views

Category:

Documents


0 download

TRANSCRIPT

  • 8/8/2019 Pharma Report Anti Infect Ives

    1/39

    ANTIINFECTIVES

    Group Report by G27

  • 8/8/2019 Pharma Report Anti Infect Ives

    2/39

    I. Definition of Terms

    Antibacterials/Antimicrobials

    Substances that inhibit the growth of orkill bacteria and other microorganisms

    (viruses, fungi, protozoa and ricketssiae)

    Are either obtained from natural sources

    or manufactured

  • 8/8/2019 Pharma Report Anti Infect Ives

    3/39

    .

    Antibiotics

    Work with the bodys natural defenses

    Chemicals that are produced by another

    kind of antibiotic that inhibit the growth

    of or kill another

  • 8/8/2019 Pharma Report Anti Infect Ives

    4/39

    Bacteriostatic

    Inhibit thegrowth of bacteria

    Bactericidal

    Killbacteria

  • 8/8/2019 Pharma Report Anti Infect Ives

    5/39

    Narrow-Spectrum Antibiotics

    Primarily effective against one type oforganism (e.g. Penicillin and

    Erythromycin are used to treat infections

    cause by gram-positive bacteria)

    Broad-Spectrum Antibiotics

    Can be effective against both gram-positive and gram-negative organisms

  • 8/8/2019 Pharma Report Anti Infect Ives

    6/39

  • 8/8/2019 Pharma Report Anti Infect Ives

    7/39

    III. Other factors that influence the

    bodys ability to fight infection

    Age

    Ig (A, E, G)Nutrition

    Organ function

    WBC

    Circulation

  • 8/8/2019 Pharma Report Anti Infect Ives

    8/39

    V. General Adverse Reactions to

    Antibacterials:1. Allergic reactions rash, pruritus,

    hives; anaphylactic shock (vascular

    shock, laryngeal edema, brochospasm,cardiac arrest, SOB)

    Tx: mild allergic rxn: antihistamineanaphylaxis: epinephrine,

    bronchodilators and antihistamines

  • 8/8/2019 Pharma Report Anti Infect Ives

    9/39

    2. Superinfection secondary infection;

    occurs when the normal flora is

    distributed by the antibiotic therapy.

    3. Organ Toxicity causes damage to

    organs (kidneys, liver)

  • 8/8/2019 Pharma Report Anti Infect Ives

    10/39

    V. What is Penicillin?

    miracle drug

    interferes with bacterial cell wall

    synthesis by inhibiting the bacterial

    enzyme that is necessary for cell division

    and cellular synthesis. The bacteria die

    of cell lysis (cell breakdown)

  • 8/8/2019 Pharma Report Anti Infect Ives

    11/39

    Classes of Penicillin:

    a. Broad-Spectrum Penicillins

    (Aminopenicillins)

    Used to treat both gram-positive and

    gram-negative bacteria

    Not penicillinase resistant

  • 8/8/2019 Pharma Report Anti Infect Ives

    12/39

    Readily inactivated by beta-lactamases,thus becoming ineffective against S.

    aureus (e.g. ampicillin (Omnipen),

    amoxicillin (Amoxil), and bacampicillin(Spectrobid).

    Amoxicillin is the most prescribedpenicillin derivative for adults and

    children.

  • 8/8/2019 Pharma Report Anti Infect Ives

    13/39

    b. Penicillinase-Resistant Penicillins(Antistaphylococcal Penicillins)

    Treats penicillinase-producing S. aureus

    Oral Forms: Cloxacilli (Cloxapen) and

    dicloxacillin (Dynapen)

  • 8/8/2019 Pharma Report Anti Infect Ives

    14/39

    IM and IV forms: nafcillin (Unipen) andoxacillin (Prostaphin)

    Not effective against gram-negativeorganisms, and less effective than

    penicillin G against gram-positive

    organisms.

  • 8/8/2019 Pharma Report Anti Infect Ives

    15/39

    c. Extended-Spectrum Penicillins

    (Antipseudomonal Penicillins)

    Group of broad-spectrum penicillins

  • 8/8/2019 Pharma Report Anti Infect Ives

    16/39

    Effective against Pseudomonas

    aeruginosa, a gram-negative bacillusthat is difficult to eradicate.

    Not penicillinase-resistant

    Pharmacologic action is similar to that

    of aminoglycosides, but are less toxic.

  • 8/8/2019 Pharma Report Anti Infect Ives

    17/39

    d.Beta-Lactamase Inhibitors

    Inhibits the bacterial beta-lactamases,

    making the antibiotic effective and

    extending its antimicrobial effect

    3 beta-lactamase inhibitors:1. clavulanic acid2. sulbactam

    3. tazobactam

  • 8/8/2019 Pharma Report Anti Infect Ives

    18/39

    Are not given alone but are combined

    with a penicillinase-sensitive penicillin

    such as amoxicillin, ampicillin,

    piperacillin and ticarcillin

    Oral use: amoxicillin-clavulanic acid

    (Augmentin)

    Parenteral use: ampicillin-sulbactam(Unasyn), piperacillin-tazobactam

    (Zosyn), and ticarcillin-clavulanic acid

    (Timentin)

  • 8/8/2019 Pharma Report Anti Infect Ives

    19/39

    Drug Interactions

    Broad-spectrum penicillins (amoxicillin

    and ampicillin) may decrease the

    effectiveness of oral contraceptives.

    Potassium supplements can increase

    the serum potassium levels when takingpotassium penicillin G orV.

  • 8/8/2019 Pharma Report Anti Infect Ives

    20/39

    When penicillin is mixed with an

    aminoglycoside in IV solution, theactions of both drugas are inactivated.

  • 8/8/2019 Pharma Report Anti Infect Ives

    21/39

    NURSING PROCESS: Penicillins

    Assessment:

    Assess for allergy to penicillin.

    Check for lab results especially liver enzymes.

    Report elevated alkaline phosphatase,

    alanine aminotransferase, aspartateaminotransferase.

    Record urine output. If the amount isinadequate (

  • 8/8/2019 Pharma Report Anti Infect Ives

    22/39

    Nursing Diagnosis:

    Risk for infection

    Risk for impaired tissue integrity

    N

    oncompliance with drug regimen

    Planning:

    Clients infection will be controlled and

    later eliminated.

  • 8/8/2019 Pharma Report Anti Infect Ives

    23/39

    Nursing Interventions:

    Check for signs and symptoms of

    superinfection, especially for clients

    taking high doses of the antibiotic for aprolonged time. S/sx include stomatitis

    (mouth ulcers), genital discharge

    (vaginitis), and anal or genital itching.

  • 8/8/2019 Pharma Report Anti Infect Ives

    24/39

    Examine client for allergic reaction to

    the penicillin product, especially afterthe first and second doses. This may be

    a mild reaction, such as a rash, or a

    severe reaction, such as respiratorydistress or anaphylaxis.

    Have EPINEPHRINE available tocounteract a severe allergic reaction.

  • 8/8/2019 Pharma Report Anti Infect Ives

    25/39

    Client Teaching:

    Instruct client to take all of the

    prescribed penicillin product such asamoxicillin until the bottle is empty. If

    only a portion of the penicillin is taken,

    drug resistance to that antibacterialagent may develop in the future.

  • 8/8/2019 Pharma Report Anti Infect Ives

    26/39

    Advise client who is allergic to penicillin

    to wear a medical alert bracelet ornecklace and carry a card that indicates

    the allergy.

    Keep drugs out of the reach of smallchildren. Request childproofcontainers.

    Inform client to report any side effects

    or adverse reaction that may occur whiletaking the drug.

  • 8/8/2019 Pharma Report Anti Infect Ives

    27/39

    Encourage client to increase fluid

    intake; fluid aid in decreasing body

    temperature and in excreting the drug.

    Instruct client or childs parent that

    chewable tablets must be chewed orcrushed before swallowing.

    Advise client to take medication with

    food if gastric irritation occurs and totake oral penicillin 1 hour before or 2

    hours after meals to avoid delay in drug

    absorption.

  • 8/8/2019 Pharma Report Anti Infect Ives

    28/39

    Evaluation:

    Clients infection wascontrolled/eliminated.

  • 8/8/2019 Pharma Report Anti Infect Ives

    29/39

    CEPHALOSPORINS

    Active against gram-positive and gram-

    negative bacteria and resistant to beta-

    lactamase (an enzyme that acts against beta-

    lactam structure of penicillin)

    Have a beta-lactam structure and act by

    inhibiting the bacterial enzyme that isnecessary for cell wall synthesis. Lysis to the

    cell occurs, and the bacterial cell dies.

  • 8/8/2019 Pharma Report Anti Infect Ives

    30/39

    Generations ofCephalosporins

    First generation:

    Effective against gram-positive bacteria such

    as Streptococci and most Staphylococci.

    Effective against most gram-negativebacteria such as E. Coli and species of

    Klebsiella, Proteus, Salmonella and Shigella.Destroyed by beta lactamases

  • 8/8/2019 Pharma Report Anti Infect Ives

    31/39

    Second generation:

    Same effectiveness as the first

    generation.

    Possesses a broader spectrum againstother gram-negative bacteria such as H.Influenza,N. Gonorrhea,N.

    Meningitidis etc.Not all is affected by beta-lactamases.

  • 8/8/2019 Pharma Report Anti Infect Ives

    32/39

    Third generation:

    Same effectiveness as the first and

    second generations.

    Less effective against gram-positive

    bacteria.

    Effective in treating sepsis and many

    strains of gram-negative bacilli.

  • 8/8/2019 Pharma Report Anti Infect Ives

    33/39

    Fourth generation:

    Similar to the third generation.

    Resistant to most beta-lactamase

    bacteria.Has a broader gram-positive coverage

    than the third generations.

    Also effective in treating sepsis andmany strains of gram-negative bacilli.

  • 8/8/2019 Pharma Report Anti Infect Ives

    34/39

    NURSING PROCESS:Cephalosporins

    Assessment:

    Assess for allergy to cephalosporins.

    RecordVS andUrine Output.

    Nursing Diagnosis:

    Risk for infection

    Noncompliance with drug regimen

  • 8/8/2019 Pharma Report Anti Infect Ives

    35/39

    Planning:

    Clients infection will be controlled and

    later eliminated.

    Nursing Interventions:

    Check for s/sx ofsuperinfection.

  • 8/8/2019 Pharma Report Anti Infect Ives

    36/39

    Refrigerate oral suspensions. For IV

    cephalosporins, dilute in an appropriateamount ofIV fluids (5-100 ml).

    Administer

    IVcephalosporins over 30-45minutes 2 to 4 times a day.

    MonitorVS, urine output. Reportabnormal findings.

  • 8/8/2019 Pharma Report Anti Infect Ives

    37/39

    Client Teaching:

    Instruct client to report signs and

    symptoms ofsuperinfection, such as

    mouth ulcers or discharge from the analor genital area.

    Advise client to ingest buttermilk oryogurt to prevent superinfection of the

    intestinal flora with long term use of

    cephalosporin.

  • 8/8/2019 Pharma Report Anti Infect Ives

    38/39

    Instruct client to take complete course ofmedication even when symptoms of infection

    have ceased.

    Instruct client to report any side effects from

    use of oral cephalosporin drugs; they mayinclude anorexia, nausea, vomiting,headache, dizziness, itching and rash.

    Advise client to take medication with food ifgastric irritation occurs.

  • 8/8/2019 Pharma Report Anti Infect Ives

    39/39

    Infuse all IV cephalosporins over 30

    minutes or as ordered to prevent painand irritation.

    Observe for hypersensitivity reactions.

    Evaluation:

    Client infection wascontrolled/eliminated.